Illustrative image.
Adcetris
Brentuximab Vedotin
$5965.00
50mg · 50 vial
BrandBranded medicine· By Takeda
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningProgressive multifocal leukoencephalopathy (pml)
JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS.
About Adcetris
Overview
Adcetris contains brentuximab vedotin, an antibody linked to an anticancer medicine, supplied as a powder in a vial for injection. It treats certain types of classical Hodgkin lymphoma, T-cell lymphoma and large B-cell lymphoma in adults, depending on previous treatment and other eligibility criteria. It is also used with chemotherapy for previously untreated, high-risk classical Hodgkin lymphoma in children aged 2 years and older. It targets a protein called CD30 on cells and releases a substance inside them that disrupts cell division and can cause the cells to die.
What it treats
- Previously untreated stage III or IV classical Hodgkin lymphoma in adults, in combination with chemotherapy. - Previously untreated high-risk classical Hodgkin lymphoma in children aged 2 years and older, in combination with chemotherapy. - Classical Hodgkin lymphoma in adults at high risk of relapse or progression, as additional treatment after an autologous stem cell transplant. - Classical Hodgkin lymphoma in adults after an autologous stem cell transplant has failed, or after at least two prior multi-drug chemotherapy regimens have failed when transplant is not an option. - Previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas in adults, in combination with chemotherapy. - Systemic anaplastic large cell lymphoma in adults after at least one prior multi-drug chemotherapy regimen has failed. - Primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides in adults who have received previous systemic treatment. - Large B-cell lymphoma that has returned or not responded after at least two lines of systemic treatment in adults who are not eligible for an autologous stem cell transplant or CAR T-cell therapy. It is used with lenalidomide and a rituximab product. This includes diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma.
Safety information
Side effects
Common side effects include nerve problems (peripheral neuropathy), nausea, tiredness, muscle and joint pain, constipation, diarrhea, vomiting, fever, upper respiratory tract infections, inflammation of the mouth or other mucous membranes, abdominal pain and rash. Blood tests may show low levels of certain white blood cells or hemoglobin, increased creatinine, high blood sugar or raised liver enzymes. Contact your doctor promptly for nerve problems, signs of infection, or new or worsening breathing or digestive symptoms. Serious risks include severe allergic reactions and infusion reactions, low blood cell counts, serious bacterial, fungal or viral infections, liver damage, lung toxicity, serious digestive complications and high blood sugar. Severe allergic reactions and severe skin reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis, require immediate medical attention. Other serious risks include tumor lysis syndrome and progressive multifocal leukoencephalopathy, a serious brain condition. Toxicity may be increased in people with severe kidney impairment or moderate to severe liver impairment. Your healthcare team will monitor blood counts, liver tests and other signs of these complications.
FDA boxed warning
Progressive multifocal leukoencephalopathy (pml)
JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not use Adcetris with bleomycin because of the risk of lung toxicity. Conditions requiring caution and close monitoring include nerve damage (peripheral neuropathy), blood cell abnormalities, infections, liver problems, lung problems, and high blood sugar. Moderate or severe liver impairment or severe kidney impairment can increase exposure to MMAE, a component of the medicine, and increase adverse reactions. Rapidly growing tumours or a high tumour burden require close monitoring for tumour lysis syndrome. Serious allergic and infusion reactions, severe skin reactions, and gastrointestinal complications may occur. An infusion reaction requires interruption of the infusion; anaphylaxis requires immediate discontinuation. Treatment must be stopped if Stevens–Johnson syndrome or toxic epidermal necrolysis occurs. Adcetris can harm an unborn baby. Females who can become pregnant and males with female partners who can become pregnant should use effective contraception. Women should not breastfeed during treatment.
Interactions
Strong CYP3A4 inhibitors or inducers may change exposure to monomethyl auristatin E (MMAE), a component of Adcetris. Ask your doctor whether any medicines you take fall into these groups.
Using Adcetris
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label ADCETRIS (BRENTUXIMAB VEDOTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [SEAGEN INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00